{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10531","value":"33668"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Evaluation of Vz/F following a single dose of 240 µg/kg plerixafor administered after 4 days of G-CSF mobilization. Vz/F was determined from non-compartmental analysis.","dispersionType":"Standard Deviation","groups":[{"description":"Subgroup of 13 participants (5 NHL and 8 MM) for which a pharmacokinetic (PK) profile was analyzed. Participants were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days, followed by plerixafor 240 µg/kg the evening of day 4.","id":"OG000","title":"PK Subgroup"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic analysis was performed on a subgroup of participants from both treatment arms (5 NHL and 8 MM).","reportingStatus":"POSTED","timeFrame":"Day 5 - 0 to 10 hours post-first plerixafor dose.","title":"Single-dose Apparent Volume of Distribution of Plerixafor (Vz/F) in NHL and MM Patients","type":"SECONDARY","unitOfMeasure":"mL"}